Differential targets engaged by narazaciclib in comparison to the approved CDK4/6 inhibitors contribute to enhanced inhibition of tumor cell growthPetros Kechagioglou,Camille Dupont,Hajime Yurugi,Ute Distler,Stefan Tenzer,Alexey Chernobrovkin,Kristina Riegel, Juliane Mooz, Mahil Lambert,Volker Dotsch, Stephen Cosenza, Steven M. Fruchtman,Krishnaraj RajalingamCANCER RESEARCH(2023)引用 0|浏览4暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要